

CIRRICULUM VITAE
SANDEEP R. BHAVE, MD, MS, DABR

OFFICE ADDRESS

Practice Locations Franciscan Health Indianapolis
Cancer Center, Radiation Oncology
8111 S. Emerson Avenue, Suite 103
Indianapolis, IN 46237
(317) 528-5171

Franciscan Health Mooresville
1215 Hadley Road- Suite 105
Mooresville, IN 46158
(317) 834-5900

Business Office Cancer Care Group, PC
6100 W. 96th Street, Suite 125
Indianapolis, Indiana 46278
Phone: (317) 715- 1800
Fax: (317) 715-6200

PROFESSIONAL EXPERIENCE

07/2019 – Associate Radiation Oncologist, Cancer Care Group, P.C. – Indianapolis, IN

POST-GRADUATE TRAINING

Residency The University of Chicago Medicine – Chicago, IL
07/2015 –06/2019 Department of Radiation and Cellular Oncology

Externship Northwestern Medicine Chicago Proton Center – Warrenville, IL
05/2019 –06/2019 Proton Radiation Therapy

Internship Presence Saint Francis Hospital – Evanston, IL
07/2014 –06/2015 Transitional Year

EDUCATION

07/2017 – 06/2019 M.S., The University of Chicago – Chicago, IL
Department of Public Health Sciences

06/2012 – 05/2014 M.D., Washington University School of Medicine – Saint Louis, MO

06/2009 – 05/2012 Vanderbilt University School of Medicine – Nashville, TN

08/2005 – 05/2009 B.S., Duke University– Durham, NC
cum laude, Psychology (Graduation with Distinction) & Biology
Neuroscience and Pharmacology Concentrations, Chemistry Minor

BOARD CERTIFICATION

5/2021 American Board of Radiology
Certification in Radiation Oncology

LICENSURE

2019- present Permanent Medical License, Indiana

PROFESSIONAL ORGANIZATIONS

2015 – present American Society for Radiation Oncology (ASTRO)

LEADERSHIP

07/2018 – 06/2019 Chief Resident, University of Chicago

HONORS/AWARDS

06/2011-5/2012 Vanderbilt Medical Scholars Program
• \$27,000 Stipend for one-year research fellowship at Washington University

05/2007-07/2007 Mechanisms of Behavior Summer Research Program
• Awarded \$5,000 National Science Foundation neuroscience fellowship

06/2005 National Advanced Placement Scholar

VOLUNTEERING

01/2017-present Undergraduate Admissions Interviewer, Duke University

PUBLISHED PEER-REVIEWED PUBLICATIONS

1. Mani S, Chen Y, Arlinghaus A, Li X, Chakravarthy A, **Bhave SR**, Welch EB, Levy MA, Yankeelov TE. Early prediction of the response of breast tumors to neoadjuvant chemotherapy using quantitative MRI and machine learning. *AMIA Annu Symp Proc.* 2011: 868-77. Epub 2011 Oct 22. PMID: 22195145.
2. Jacobs KM, **Bhave SR**, Ferraro DJ, Jaboin JJ, Hallahan DE, Thotala DT. GSK-3 β : A Bifunctional Role in Cell Death Pathways. *Int J Cell Biol.* 2012; 2012:930710. Epub 2012 May 21. PMID: 22675363.
3. Ferraro DJ, **Bhave SR**, Kotipatruni RP, Hunn JC, Wildman SA, Hong C, Dadey DYA, Muhoro LK, Jaboin JJ, Thotala D, Hallahan DE. High throughput identification of the protein ligands of cancer-binding peptides using biopanning and microarray analysis. *Integr Biol (Camb).* 2012 Nov 13. PMID: 23147990.
4. Mani S, Chen Y, Li X, Arlinghaus L, Chakravarthy AB, Abramson V, **Bhave SR**, Levy MA, Xu H, Yankeelov TE. Machine learning for predicting the response of breast cancer to neoadjuvant chemotherapy. *J Am Med Inform Assoc.* 2013 Apr 24. PMID: 23616206.
5. Li X, Arlinghaus LR, Chakravarthy AB, Abramson RG, Abramson VG, Atuegwu N, Farley J, Ayers GD, Mayer IA, Kelley MC, Meszoely IM, Means-Powell J, Grau AM, Sanders M, **Bhave SR**, Yankeelov, TE. Towards optimization of DCE-MRI analysis for predicting treatment response to neoadjuvant chemotherapy in breast cancer. *Magn Reson Med.* 2013 May 9. PMID: 23661583.

6. Thotala D, Craft JM, Kotiputruni R, **Bhave SR**, Jaboin JJ, Hallahan DE. Cytosolic PhospholipaseA2 Inhibition with PLA-695 Radiosensitizes Tumors in Lung Cancer Animal Models. *PLoS One*. 2013. Jul 22. PMID: 23894523.
7. **Bhave SR**, Dadey DYA, Karvas RM, Ferraro DJ, Kotipatruni RP, Jaboin JJ, DeWees TA, Linkous AG, Hallahan DE, Thotala DT. Inhibition of autotaxin enhances radiation-induced cytotoxicity and disrupts pro-survival signaling in human and murine malignant glioma cell lines. *Front Oncol*. Sept 17 2013; 3:236. PMID: 24062988.
8. Korpics MC, Polley M, **Bhave SR**, Redler G, Pitroda SP, Luke JJ, Chmura SJ. A validated t cell radiomics score is associated with clinic outcomes following multi-site SBRT and pembrolizumab. *Int J Radiat Oncol Biol Phys*. 2020 Jun 19. PMID: 32569799
9. Luke JJ, Onderdonk BE, **Bhave SR**, Karrison T, Lemons JM, Chang P, Zha Y, Carll T, Krausz T, Huang L, Martinez CA, Janisch LA, Hseu R, Moroney JW, Patel JD, Khodarev NN, Salama JK, Ott PA, Fleming GF, Gajewski TF, Weichselbaum RR, Pitroda SP, Chmura SJ. Improved survival associated with local tumor response following multi-site radiotherapy and pembrolizumab: secondary analysis of a phase I trial. *Clin Cancer Res*. 2020 Oct 7. PMID: 33028595

ORAL PRESENTATIONS

1. Onderdonk BE, Luke JJ, **Bhave SR**, Karrison TG, Chang P, Zha Y, Carll T, Krausz TN, Huang L, Janisch L, Hseu R, Khodarev N, Weichselbaum RR, Pitroda SP, Chmura SJ. Multi-Site SBRT and sequential pembrolizumab: treated metastasis control and immune-related expression.
 - American Society for Therapeutic Radiation Oncology (ASTRO) Annual Meeting, Chicago, IL– 8/2019
2. Korpics MC, **Bhave SR**, Redler G, Pitroda S, Luke JJ, Chmura SJ. A validated radiomics T cell score predicts response to multi-site SBRT combined with pembrolizumab.
 - American Society for Therapeutic Radiation Oncology (ASTRO) Annual Meeting, Chicago, IL– 8/2019

POSTER PRESENTATIONS

1. **Bhave SR**, Luke JJ, Lemons JM, Janisch LA, Hseu RD, Chmura SJ. Expansion Cohort of Partially Irradiated Tumors on a Phase 1 Trial of Pembrolizumab and Ablative Radiotherapy.
 - American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL – 6/2018
2. **Bhave SR**, Koshy M, Akthar AS, Sengul A, Weichselbaum RR, Patel P, Rondelli D, Aydrogan B. Long-term toxicities using intensity modulated total marrow irradiation (IM-TMI) as part of conditioning regimen for advanced hematologic malignancies.
 - American Society for Therapeutic Radiation Oncology (ASTRO) Annual Meeting, San Diego, CA– 9/2017
3. **Bhave SR**, Koshy M, Akthar AS, Sengul A, Weichselbaum RR, Patel P, Rondelli D, Aydrogan B. Prospective Assessment of Radiation Dose Toxicity Correlations in Patients Who Received Intensity Modulated Total Marrow Irradiation (IM-TMI) as Part of Conditioning Regimen Prior to Stem Cell Transplant.
 - American Society for Therapeutic Radiation Oncology (ASTRO) Annual Meeting, Boston, MA– 9/2016
4. **Bhave SR**, Dadey DYA, Ferraro DJ, Karvas RK, Hallahan DE, Thotala DT. Inhibition of autotaxin enhances radiosensitivity in human and murine glioblastoma cell lines.
 - American Association for Cancer Research Annual Meeting, Washington D.C. – 4/2013
5. Li X, Arlinghaus LR, Chakravarthy AB, Abramson RG, Abramson VG, Farley J, Ayers GD,

- Mayer IA, Kelley MC, Meszoely IM, Means-Powell J, Grau AM, Sanders M, **Bhave SR**, Yankeelov TE. Quantitative DCE- and DW-MRI to Predict the Response of Primary Breast Cancer to Neoadjuvant Therapy
- International Society for Magnetic Resonance in Medicine Annual Meeting, Salt Lake City, UT – 4/2013
6. **Bhave SR**, Ferraro DJ, Karvas RK, Linkous AG, Hallahan DH, Thotala DT. Inhibition of autotaxin enhances radiosensitivity in human and murine malignant glioblastoma cell lines.
 - Radiation Research Society Annual Meeting, San Juan, Puerto Rico – 9/2012
 7. Li X, Arlinghaus LR, Dawant BM, Chakravarthy AK, Welch EB, Farley J, Mayer IA, Abramson VG, Kelley MC, Meszoely IM, Means-Powell JA, Grau AM, **Bhave SR**, Yankeelov TE. *Voxel-based Analysis of Early DCE-MRI Changes May Predict the Response to Neoadjuvant Chemotherapy in Breast Cancer Patients.*
 - International Society for Magnetic Resonance in Medicine Annual Meeting, Melbourne, Australia – 5/2012
 8. Li X, Arlinghaus LR, Chakravarthy AK, Welch EB, Farley J, Mayer IA, Abramson VG, Abramson RG, Kelley MC, Meszoely IM, Means-Powell JA, Grau AM, **Bhave SR**, Yankeelov TE. *Towards Optimization of DCE-MRI Analysis for Early Prediction of the Response of Breast Cancer Patients to Neoadjuvant Chemotherapy.*
 - International Society for Magnetic Resonance in Medicine Annual Meeting, Melbourne, Australia – 5/2012
 9. Sweeney KR, **Bhave S**, Hu R, Fong J, DeWees TA, Hallahan DE, Thotala DK. *Valproic Acid Enhances Radiation Therapy by Protecting Normal Hippocampal Neurons and Sensitizing Malignant Glioblastoma Cells.*
 - American Association for Cancer Research Annual Meeting, Chicago, IL – 4/2012
 10. **Bhave SR**, Sweeney KR, Hu R, Fong J, DeWees TA, Hallahan DE, Thotala DK. *Valproic Acid Enhances Radiation Therapy by Protecting Normal Hippocampal Neurons and Sensitizing Malignant Glioblastoma Cells.*
 - Second Annual Retreat, Hope Center for Neurological Disorders, Washington University School of Medicine – 3/2012
 11. **Bhave SR**, Recchia FM. *Anatomic and Visual Outcomes following Vitrectomy for Vitreomacular Disorders.*
 - Emphasis Forum, Vanderbilt University School of Medicine – 5/2011
 12. Chakravarthy A, **Bhave SR**, Li X, Welch B, Arlinghaus L, Farley J, Mayer A, Kelley M, Meszoely I, Yankeelov TE. *Developing Imaging Markers of Response to Neoadjuvant Chemotherapy in Stage II/III Breast Cancer.*
 - Cancer Imaging and Radiation Therapy Symposium, Atlanta, GA – 4/2011
 13. **Bhave SR**. *A Novel Neural Mechanism Underlying OCD-Like Behaviors.*
 - Visible Thinking, Candidates for Graduation with Distinction in Psychology, Duke University – 4/2009
 14. **Bhave SR**, Cheng RK, Meck WH. *The Metabotropic Glutamate 2/3 Receptor Agonist LY379268 Counteracts the Clock-Speed Enhancing Effects of Cocaine.*
 - Society for Neuroscience 38th Annual Meeting, Washington, DC – 11/2008
 15. Cordes SA, Williamson LA, Alves K, **Bhave SR**, Rodriguiz RM, Wetsel WC, Meck WH. *The Role of the Norepinephrine Transporter in Interval Timing.*
 - Poster: Society for Neuroscience 38th Annual Meeting, Washington, DC – 11/2008

16. **Bhave SR**, Cheng RK, Meck WH. *The Metabotropic Glutamate 2/3 Receptor Agonist LY379268 Interacts with Cocaine in Interval Timing.*
 - Trinity College Research Forum in Neuroscience, Duke University, – 4/2008